Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations.
In five nondemented Parkinson's disease patients with daily visual hallucinations, we tested whether high-dose IV levodopa (LD) infusions precipitated hallucinations. Two infusion paradigms were studied, each with 1.5-mg/kg hourly dose for 4 hours--steady infusion and pulse infusion of the full hour dose over 5 minutes each hour. In both protocols, plasma LD levels changed significantly during the infusion protocol. The cumulative area under the curve was equivalent for the two infusions. All patients remained alert, and none developed visual hallucinations. The two patients with peak-dose dyskinesias on oral LD developed prominent dyskinesias during the infusion. Visual hallucinations do not relate simply to high levels of LD or to sudden changes in plasma levels.
Goetz
C G
CG
Department of Neurological Sciences, Rush University/Rush Presbyterian St. Luke's Medical Center, Chicago, IL, USA.
Pappert
E J
EJ
Blasucci
L M
LM
Stebbins
G T
GT
Ling
Z D
ZD
Nora
M V
MV
Carvey
P M
PM
D000368:Aged; D000978:Antiparkinson Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D004334:Drug Administration Schedule; D005260:Female; D006212:Hallucinations / Q000139:chemically induced / Q000209:etiology*; D006801:Humans; D007262:Infusions, Intravenous; D007980:Levodopa / Q000008:administration & dosage / Q000009:adverse effects* / Q000097:blood; D008297:Male; D010300:Parkinson Disease / Q000150:complications* / Q000188:drug therapy / Q000523:psychology; D013997:Time Factors
D000978:Antiparkinson Agents; D007980:Levodopa